Summit Therapeutics to Participate in Upcoming Investor Conferences
14 September 2018 - 5:00PM
Summit Therapeutics plc (‘Summit’ or the
’Company’)
Summit Therapeutics to Participate in Upcoming Investor
Conferences
Oxford, UK, and Cambridge, MA, US, 14
September 2018 – Summit Therapeutics plc (NASDAQ: SMMT, AIM:
SUMM) announces that management will participate in one on one
meetings for two upcoming investor conferences in New York
City.
- Janney Healthcare Conference: 17 September 2018
- Oppenheimer Fall Summit: 26 September 2018
There will be no podium presentations at these meetings.
About Summit Therapeutics Summit
Therapeutics is a leader in antibiotic innovation. Our new
mechanism antibiotics are designed to become the new standards of
care for the benefit of patients, and create value for payors and
healthcare providers. We are currently developing new mechanism
antibiotics for C. difficile infection and gonorrhoea and are using
our proprietary Discuva Platform to expand our pipeline. For more
information, visit www.summitplc.com and follow us on Twitter
@summitplc.
Contacts
Summit |
|
|
Glyn Edwards / Richard Pye (UK office) |
Tel: |
44 (0)1235 443 951 |
Erik Ostrowski / Michelle Avery (US office) |
|
+1 617 225 4455 |
|
|
|
Cairn Financial Advisers LLP (Nominated
Adviser) |
Tel: |
+44 (0)20 7213 0880 |
Liam Murray / Tony Rawlinson |
|
|
|
|
|
N+1 Singer (Joint Broker) |
Tel: |
+44 (0)20 7496 3000 |
Aubrey Powell / Jen Boorer, Corporate FinanceTom
Salvesen, Corporate Broking |
|
|
|
|
|
Panmure Gordon (Joint Broker) |
Tel: |
+44 (0)20 7886 2500 |
Freddy Crossley, Corporate FinanceJames Stearns,
Corporate Broking |
|
|
|
|
|
MSL Group (US) |
Tel: |
+1 781 684 6557 |
Jon Siegal |
|
summit@mslgroup.com |
|
|
|
Consilium Strategic Communications (UK) |
Tel: |
+44 (0)20 3709 5700 |
Mary-Jane Elliott / Jessica Hodgson / |
|
summit@consilium-comms.com |
Lindsey Neville |
|
|
-END-
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Jul 2023 to Jul 2024